Bearpac Medical has signed an agreement with UK-based APR Medtech for the distribution of its Passio pump drainage system.

The agreement will allow Bearpac to bring the system to the UK healthcare sector.

The Passio pump is designed for the drainage of recurrent and symptomatic pleural effusions and malignant ascites.

The system comprises a Passio catheter, a handheld control unit (pump) and a disposable collection kit, which includes a redressing kit for drainage of pleural effusions and ascites.

In August 2020, Bearpac Medical announced the launch of the FDA 510(k) cleared Passio pump drainage system.

Bearpac Medical president Jay Zimmerman said: “This agreement with APR Medtech presents a significant market opportunity for our Passio Pump Drainage System, now with an expanded CE certification to include both pleural and peritoneal indications.”

Using the disposable collection kit, the Passio pump is connected to an implanted Passio catheter and triggered to initiate fluid evacuation into the collection bag.

The Passio catheter is only designed for use with the Passio collection system.

Recently, Bearpac Medical has received CE Mark certification for the Passio pump drainage system to market the pump in European Economic Area (EEA) member countries.

APR Medtech technical director Michael Pichel said: “The Passio Pump Drainage System is an innovative, next generation product and we are delighted to be partnering with Bearpac Medical to bring this technology to the NHS and UK private healthcare sector.”

Headquartered in New Hampshire, Bearpac Medical is engaged in the development of thoracic drainage products.